DeepMed Research

TARGACEPT, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Employees: -

Market Cap: -

Website: http://www.targacept.com

Clinical Trials

Study Evaluating the Effect of TC-6499 on Gastric Emptying Time in Diabetic Subjects With Gastroparesis

Phase 1

Completed

Conditions: Gastroparesis

Interventions: Drug: TC-6499
Drug: Placebo

First Posted Date: 2014-07-10

Last Posted Date: 2015-05-12

Lead Sponsor: Targacept Inc.

Target Recruit Count: 80

Registration Number: NCT02187094

Locations: 🇺🇸
Quality Medical Research, Nashville, Tennessee, United States
🇺🇸
Aspen Clinical Research, LLC, Orem, Utah, United States
🇺🇸
Horizon Research Group, Inc., Mobile, Alabama, United States

and more 5 locations

Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder

Phase 2

Completed

Conditions: Overactive Bladder

Interventions: Drug: dexmecamylamine
Drug: Placebo

First Posted Date: 2013-06-04

Last Posted Date: 2015-06-03

Lead Sponsor: Targacept Inc.

Target Recruit Count: 1635

Registration Number: NCT01868516

Locations: 🇺🇸
Palm Beach Research Center, West Palm Beach, Florida, United States
🇺🇸
Westside Family Medical Center, PC, Kalamazoo, Michigan, United States
🇺🇸
Coastal Clinical Research, Inc., Mobile, Alabama, United States

and more 107 locations

Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia

Phase 2

Completed

Conditions: Cognitive Dysfunction
Schizophrenia
Negative Symptoms

Interventions: Drug: TC-5619
Drug: Placebo

First Posted Date: 2011-12-08

Last Posted Date: 2015-06-03

Lead Sponsor: Targacept Inc.

Target Recruit Count: 603

Registration Number: NCT01488929

Locations: 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸
Behavorial Research Specialists, Glendale, California, United States
🇺🇸
Midwest Clinical Research Center, Dayton, Ohio, United States

and more 61 locations

Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)

Phase 2

Completed

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: TC-5619-238 25mg
Drug: Placebo
Drug: TC-5619-238 5mg

First Posted Date: 2011-11-17

Last Posted Date: 2013-04-30

Lead Sponsor: Targacept Inc.

Target Recruit Count: 250

Registration Number: NCT01472991

Locations: 🇺🇸
Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States
🇺🇸
Compass Research, Inc., Orlando, Florida, United States
🇺🇸
Florida Clinical Research Center, LLC, Maitland, Florida, United States

and more 9 locations

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: AZD3480
Drug: Donepezil

First Posted Date: 2011-11-06

Last Posted Date: 2015-06-03

Lead Sponsor: Targacept Inc.

Target Recruit Count: 386

Registration Number: NCT01466088

Locations: 🇺🇦
Odessa Regional Psychoneurology Dispensary, Odessa, Ukraine
🇺🇦
Dnipropetrovsk Regional Clinical Hospital, Dnipropetrovsk, Ukraine
🇺🇦
Central Clinical Hospital Ukrzaliznytsi, Kharkiv, Ukraine

and more 30 locations

TC-6987 for the Treatment of Mild to Moderate Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: TC-6987
Drug: Placebo

First Posted Date: 2011-02-15

Last Posted Date: 2013-09-13

Lead Sponsor: Targacept Inc.

Target Recruit Count: 203

Registration Number: NCT01296087

Locations: 🇺🇸
Sarasota Clinical Research, Sarasota, Florida, United States
🇺🇸
Allergy & Asthma Research of New Jersey, Inc., Philadelphia, Pennsylvania, United States
🇺🇸
Pioneer Research Solutions, Houston, Texas, United States

and more 18 locations

Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: TC-6987
Drug: Placebo

First Posted Date: 2011-02-10

Last Posted Date: 2013-09-13

Lead Sponsor: Targacept Inc.

Target Recruit Count: 440

Registration Number: NCT01293669

Locations: 🇺🇸
PMG Research of WS, Winston-Salem, North Carolina, United States
🇺🇸
Clopton Clinic, Jonesboro, Arkansas, United States
🇺🇸
Cedar Crosse Research Center, Chicago, Illinois, United States

and more 15 locations

Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: TC-5619
Drug: Placebo

First Posted Date: 2010-12-06

Last Posted Date: 2013-09-04

Lead Sponsor: Targacept Inc.

Target Recruit Count: 38

Registration Number: NCT01254448

Locations: 🇺🇸
Collaborative Neuroscience Network, Long Beach, California, United States
🇺🇸
MD Clinical, Hallandale Beach, Florida, United States
🇺🇸
Atlanta Center For Clinical Research, Atlanta, Georgia, United States

and more 7 locations

Proof-of-Principle Study of TC-6499 in the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS)

Phase 2

Completed

Conditions: Irritable Bowel Syndrome

Interventions: Drug: TC-6499
Drug: Placebo

First Posted Date: 2010-06-23

Last Posted Date: 2013-12-02

Lead Sponsor: Targacept Inc.

Target Recruit Count: 24

Registration Number: NCT01149200

Locations: 🇬🇧
Quotient Clinical Ltd, Ruddington, United Kingdom

Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)

Phase 2

Completed

Conditions: ADHD

Interventions: Drug: Placebo
Drug: TC-5619-238

First Posted Date: 2010-05-17

Last Posted Date: 2013-09-13

Lead Sponsor: Targacept Inc.

Target Recruit Count: 134

Registration Number: NCT01124708

Locations: 🇺🇸
Claghorn-Lessem Research Clinic, Houston, Texas, United States
🇺🇸
Scientifc Clinical Research, Inc., North Miami, Florida, United States
🇺🇸
CRI Worldwide, LLC (Kirkbride Division), Philadelphia, Pennsylvania, United States

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy